Skip to content
Clinical Trials – home
Regeneron Pharmaceuticals Inc.
Sponsor

Regeneron Pharmaceuticals Inc.

United States 777 Old Saw Mill River Road, 10591-6717, United States

About the sponsor

Regeneron Pharmaceuticals Inc. funds extensive research in non-small cell lung cancer, including advanced, resectable, and biomarker-defined disease, alongside studies in melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma, ovarian cancer, and other advanced solid tumors. Its oncology portfolio also includes multiple programs in multiple myeloma, follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and high-risk monoclonal gammopathy of undetermined significance.

  • Advanced and metastatic solid tumors
  • Non-small cell lung cancer
  • B-cell non-Hodgkin lymphoma
  • Multiple myeloma and plasma cell disorders
  • Melanoma and skin cancers

Additional oncology interests extend to head and neck squamous cell carcinoma, endometrial cancer, renal-cell carcinoma, primary peritoneal cancer, and perioperative treatment strategies for surgically managed malignancies.

About Specializations

Regeneron Pharmaceuticals Inc. runs clinical trials in conditions such as Embolism, Non-small cell lung cancer, Malignant melanoma, Plasma cell myeloma refractory, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

63 clinical trials

Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Embolism

Recruiting
Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adeno-Associated Virus Vector Serotype 8 Containing The Human F9 Gene
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.